Table 4.
Correlation analyses of AOPPs with the lipid contents of HDL particles, performed separately for HVs and patients with MS.
| AOPPs (μmol/L) | ||||
|---|---|---|---|---|
| HV (N = 65) |
MS (N = 65) |
|||
| Variable | r | p | r | p |
| HDL-C/HDL-apoA-I | −0.60 | <0.0001 | −0.57 | <0.0001 |
| HDL1-C/HDL1-apoA-I | 0.34 | 0.0056 | 0.17 | 0.1702 |
| HDL2-C/HDL2-apoA-I | −0.28 | 0.0222 | −0.02 | 0.8962 |
| HDL3-C/HDL3-apoA-I | −0.40 | 0.0009 | −0.52 | <0.0001 |
| HDL4-C/HDL4-apoA-I | −0.32 | 0.0091 | −0.63 | <0.0001 |
| HDL-FC/HDL-apoA-I | −0.59 | <0.0001 | −0.27 | 0.0279 |
| HDL1-FC/HDL1-apoA-I | 0.36 | 0.0035 | −0.09 | 0.4651 |
| HDL2-FC/HDL2-apoA-I | 0.06 | 0.6221 | −0.03 | 0.8004 |
| HDL3-FC/HDL3-apoA-I | 0.07 | 0.5528 | −0.19 | 0.1278 |
| HDL4-FC/HDL4-apoA-I | 0.00 | 0.9694 | −0.29 | 0.0206 |
| HDL-TG/HDL-apoA-I | 0.39 | 0.0012 | 0.66 | <0.0001 |
| HDL1-TG/HDL1-apoA-I | 0.55 | <0.0001 | 0.71 | <0.0001 |
| HDL2-TG/HDL2-apoA-I | 0.45 | 0.0001 | 0.70 | <0.0001 |
| HDL3-TG/HDL3-apoA-I | 0.54 | <0.0001 | 0.73 | <0.0001 |
| HDL4-TG/HDL4-apoA-I | 0.55 | <0.0001 | 0.69 | <0.0001 |
| HDL-PL/HDL-apoA-I | −0.52 | <0.0001 | −0.45 | 0.0002 |
| HDL1-PL/HDL1-apoA-I | 0.34 | 0.0056 | −0.13 | 0.3132 |
| HDL2-PL/HDL2-apoA-I | −0.25 | 0.0443 | 0.05 | 0.6656 |
| HDL3-PL/HDL3-apoA-I | −0.14 | 0.2657 | −0.31 | 0.0125 |
| HDL4-PL/HDL4-apoA-I | −0.25 | 0.0435 | −0.66 | <0.0001 |
The associations between AOPPs and the lipid contents of HDL particles were evaluated with Spearman correlation analyses. p-values < 0.0003 are considered statistically significant after a Bonferroni testing for multiple comparison and are depicted in bold. AOPPs, advanced oxidation protein products; ApoA-I, apolipoprotein A-I; C, cholesterol; FC, free cholesterol; HV, healthy volunteer; HDL, high-density lipoprotein; MS, patient with metabolic syndrome; PL, phospholipid; r, Spearman’s correlation coefficient; TG, triglyceride.